CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
Kakuda
Thomas N
TN
Anderson
Peter L
PL
Becker
Stephen L
SL
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000009:adverse effects*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects*; D016049:Didanosine / Q000009:adverse effects; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D006801:Humans; D008231:Lymphopenia / Q000139:chemically induced* / Q000201:enzymology; D063065:Organophosphonates / Q000009:adverse effects; D011683:Purine-Nucleoside Phosphorylase / Q000037:antagonists & inhibitors*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D000068698:Tenofovir; D017211:Treatment Failure
D019380:Anti-HIV Agents; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D011683:Purine-Nucleoside Phosphorylase; D000225:Adenine; D016049:Didanosine